Determine your risk of passing on over 300 genetic diseases to your future child.
80% of children born with a genetic condition have no family history of that disease. CarrierMap is an expanded carrier screen that can help you plan for a healthy family.
CarrierMap is recommended for people who are planning a family or early in pregnancy.
Gain insight into the health of your pregnancy with one simple blood test.
Chromosome abnormalities such as Down syndrome impact over 1 in 107 pregnancies. ChromoMap is a non-invasive prenatal screen to assess risk for these conditions.
ChromoMap is available for women who are at least 10 weeks pregnant.
Contribute to a first-of-its-kind study on the links between genomics and infertility.
1 in 6 couples are impacted by infertility. Through large-scale research, FertilityMap seeks to optimize fertility treatment, helping more families achieve successful pregnancies.
Participation in FertilityMap is currently only open to patients of partner clinics.
Navigate the complicated world of genomics with help from Recombine’s expert genetic counselors.
Recombine is focused on comprehensive patient care and offers detailed genetic counseling pre- and post-test to help give the most complete picture of your family’s risk.
Recombine genetic counseling is available alongside CarrierMap and ChromoMap at no additional charge.
Phone: 855-OUR-GENES (855-687-4363)
Location: 1140 Broadway, Suite 1100, New York 10001
A pan-ethnic screen with 300+ conditions ›
Cutting-edge synergized technology ›
Complete genetic counseling support ›
Seamless integration into your practice ›
CarrierMap is the most comprehensive carrier screen, and includes all ACOG- and ACMG-recommended* conditions plus over 300 others. CarrierMap was designed with input from professional societies and advocacy groups worldwide, and covers the widest range of ancestries.
In today’s society, many people are multi-ethnic or do not know of their ancestry or identify with a particular ethnicity. It is therefore increasingly important to screen for diseases seen across many different populations, beyond European and Ashkenazi Jewish. CarrierMap includes conditions that are common in under-represented populations such as Asian, African, Latin American, and Native American.
*ACOG: American College of Obstetrics and Gynecology, ACMG: American College of Medical Genetics and Genomics
Recombine leverages Illumina’s powerful genotyping technology and customized next-generation sequencing (NGS) technology to better detect the most relevant diseases and mutations. Our expert team of bioinformaticists and genetic counselors is constantly iterating—adding and removing diseases and mutations based on emerging literature—to continually give you the most detailed picture of your patient’s genetic health and reproductive risks.
As a part of our commitment to responsible medicine, Recombine is proud to offer pre- and post-test genetic counseling to all patients, as well as clinician support throughout every step of the testing process.
Our board-certified expert genetic counselors will guide your patients through their results in the context of their personal and family medical history, for a more complete assessment of reproductive risk. We write up a detailed summary letter of every consult, keeping you involved and informed. For patients who are identified through CarrierMap as having a high reproductive risk, complimentary PGD is available through our partner laboratory, Reprogenetics (exclusions apply).
At Recombine, we are dedicated to providing superior testing and an overall seamless experience. We value collaborative partnerships with our providers and are always happy to adapt and respond to your practice’s unique needs.
You and your staff can view results, order kits, and check patient status online through our clinic portal. Our system also integrates with electronic medical records for optimal clinical workflow.
CarrierMap reports are available within 5-8 business days following the sample’s arrival at our CLIA-certified laboratory, and patients’ carrier status is presented clearly, along with information regarding the disease impact and risk.